HCM:NGS-Hutchison China MediTech Limited

EQUITY | Drug Manufacturers | Nasdaq Global Select

Last Closing Price

USD 39.77

Change

+0.25 (+0.63)%

Market Cap

USD 5.28B

Volume

0.08M

Yahoo Analyst Target

USD 34.67 (-12.82%)

STA Analyst Target

USD 35.33 (-11.16%)
Yahoo Analyst Rating

Verdict

STA Analyst Rating

Verdict

STA Verdict

Verdict

About

Hutchison China Meditech Ltd is a biopharmaceutical company. The Company along with its subsidiaries is engaged in researching, developing, manufacturing and selling pharmaceuticals and health-related consumer products.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2018-01-18 )

Largest Industry Peers for Drug Manufacturers

Symbol Name Price(Change) Market Cap
WBA Walgreens Boots Alliance Inc.

+0.22 (+0.29%)

USD 75.29B
MYL Mylan N.V.

-0.27 (-0.58%)

USD 24.95B
NBIX Neurocrine Biosciences Inc.

+2.68 (+3.53%)

USD 6.95B
AKRX Akorn Inc.

-0.09 (-0.27%)

USD 4.13B
GWPH GW Pharmaceuticals Plc

-0.45 (-0.34%)

USD 3.35B
HZNP Horizon Pharma plc

+0.22 (+1.47%)

USD 2.49B
IRWD Ironwood Pharmaceuticals Inc.

+0.10 (+0.67%)

USD 2.25B
SUPN Supernus Pharmaceuticals Inc.

-2.95 (-6.34%)

USD 2.23B
AERI Aerie Pharmaceuticals Inc.

+0.50 (+0.87%)

USD 2.13B
MDCO The Medicines Company

-0.34 (-1.34%)

USD 1.82B

ETFs Containing HCM

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Drug Manufacturers)
Market Performance vs. Exchange (Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 0.89% 33% F 39% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 0.89% 33% F 39% F
Trailing 12 Months  
Capital Gain 187.15% 96% A 97% A+
Dividend Return N/A N/A N/A N/A N/A
Total Return 187.15% 96% A 97% A+
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 45.92% 86% B 93% A
Dividend Return 45.92% 86% B 92% A-
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 59.63% 39% F 16% F
Risk Adjusted Return 77.01% 97% A+ 73% C
Market Capitalization 1.51B 96% A 90% A-

Key Financial Ratios

  Ratio vs. Industry/Classification
(Drug Manufacturers)
Ratio vs. Market
(Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 220.94 1% F 1% F
Price/Book Ratio 26.16 7% F 4% F
Price / Cash Flow Ratio -265.13 100% A+ 100% A+
Price/Free Cash Flow Ratio 1,988.50 1% F 0% N/A
Management Effectiveness  
Return on Equity 10.54% 79% C+ 72% C-
Return on Invested Capital -34.07% 62% D- 22% F
Return on Assets 5.40% 87% B+ 79% C+
Debt to Equity Ratio 33.25% 48% F 56% F

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters then its peers, placing it in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

What to not like:
High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Higly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector